Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Demcizumab||OMP-21M18|anti-delta-like 4 monoclonal antibody OMP-21M18||DLL4 Antibody 6||Demcizumab (OMP-21M18) is a monoclonal antibody that binds DLL4 and prevents its interaction with Notch receptors, thereby inhibiting pathway activation and tumor growth (PMID: 19664991, PMID: 25324140, PMID: 32037195).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Demcizumab||Phase I||Actionable||In a Phase I trial, treatment with Demcizumab (OMP-21M18) resulted in downregulation of Notch target genes and demonstrated preliminary efficacy in patients with advanced solid tumors, with reductions in tumor size in patients with several tumor types, including colorectal cancer (PMID: 25324140).||25324140|
|Unknown unknown||Advanced Solid Tumor||not applicable||Demcizumab||Phase I||Actionable||In a Phase I trial, treatment with Demcizumab (OMP-21M18) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 25324140).||25324140|
|Unknown unknown||ovarian cancer||not applicable||Demcizumab||Preclinical - Pdx||Actionable||In a preclinical study, Demcizumab (OMP-21M18) inhibited tumor growth in patient-derived xenograft (PDX) models of ovarian cancer (Cancer Res 2013;73(8 Suppl):Abstract nr 3725).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01952249||Phase Ib/II||Demcizumab Paclitaxel||A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian||Terminated||USA||0|
|NCT02259582||Phase II||Carboplatin + Pemetrexed Disodium Demcizumab||A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer||Completed||USA||4|